Abbott Laboratories has filed a Supplemental New Drug Application in the USA for the use of its clarithromycin antibiotic in combination with Astra/Merck's proton pump inhibitor Prilosec (omeprazole) to eradicate Helicobacter pylori and prevent peptic ulcer recurrence.
In most clinical trials of the combination, a 28-day dosing regimen comprising 500mg clarithromycin tid plus 40mg/day omeprazole for days one to 14 was used, followed by 20mg/day omeprazole for the remainder of the course. Eradication rates of over 70% have been achieved.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze